Avacta Group (LSE:AVCT) Current Deferred Revenue: £0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AVCT Avacta Group PLC LSE:AVCT
27 GF Score
Price £0.70
! 8 Warning Signs
View Full Analysis

What is Avacta Group Current Deferred Revenue?

Avacta Group LSE:AVCT +1.45% 27 Current Deferred Revenue is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:AVCT with a GF Score™ of 27/100. The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Avacta Group's current deferred revenue for the quarter that ended in Dec. 2025 was £0.00 Mil.

Avacta Group Current Deferred Revenue Related Terms

Avacta Group Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Avacta Group's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avacta Group Current Deferred Revenue Chart

Avacta Group Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avacta Group Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:AVCT
27GF Score
Avacta Group PLC LSE:AVCT
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of £0.00 Mil mean?
Avacta Group (LSE:AVCT) has a Current Deferred Revenue of £0.00 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Avacta Group and its competitors.
Is Avacta Group's Current Deferred Revenue too high?
Avacta Group's current Current Deferred Revenue is £0.00 Mil. Overall, Avacta Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Current Deferred Revenue compare to VRTX and REGN?
Avacta Group's Current Deferred Revenue of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Avacta Group and its competitors. Avacta Group's current Current Deferred Revenue is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Avacta Group (LSE:AVCT) has a current Current Deferred Revenue of £0.00 Mil. The current Current Deferred Revenue is £0.00 Mil. Avacta Group's overall GF Score™ is 27/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current Current Deferred Revenue is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avacta Group Business Description

Other Exchanges AVCTF:USARTQ1:Germany
Address 58 Wood Lane, White City Imperial College Campus, Scale Space, London, GBR, W12 7RZ
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
27GF Score

Get the complete analysis for LSE:AVCT

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.70
Price